Dr. Drew Pinsky Champions Patient Voice in Rheumatoid Arthritis Research with FORWARD

FOR IMMEDIATE RELEASE

n

Omaha, NE – In a significant convergence of medical advocacy and public awareness, renowned physician and media personality Dr. Drew Pinsky recently engaged in a compelling discussion with Dr. Kaleb Michaud, PhD, Director of the non-profit research organization FORWARD, The National Databank for Rheumatic Diseases. The conversation, which brought Dr. Pinsky’s personal journey as a lifelong patient with Rheumatoid Arthritis (RA) into sharp focus, underscored the critical mission of FORWARD: to empower individuals living with rheumatic diseases by amplifying their voices in scientific research and shaping the future of treatment and care.

n

The dialogue illuminated not only the daily realities faced by millions afflicted with chronic rheumatic conditions but also the innovative approach FORWARD employs to bridge the gap between clinical understanding and real-world patient experience. Executive Director Rebecca Schumacher, Dr. Ted Mikuls, and Teresa Kerkman also contributed insights into the organization’s multifaceted efforts, emphasizing its commitment to advancing knowledge about the causes, treatments, and outcomes related to these often debilitating conditions.

n

FORWARD’s unique model centers on the belief that patients are invaluable partners in research. By systematically collecting patient-reported data, the organization provides a comprehensive, longitudinal perspective on disease progression, treatment efficacy, and quality of life that extends far beyond the snapshot offered by a typical clinic visit. This rich tapestry of information serves as a vital resource for healthcare professionals, researchers, and ultimately, the patients themselves, fostering a more holistic and effective approach to managing rheumatic diseases.

n

The Main Facts: A Nexus of Patient Advocacy and Scientific Inquiry

n

The core of the recent discussion revolved around Dr. Drew Pinsky’s candid sharing of his experience living with Rheumatoid Arthritis. His willingness to speak openly about the challenges and triumphs of managing a chronic autoimmune condition lends a powerful human element to the often-abstract world of medical research. Dr. Pinsky’s narrative serves as a potent reminder of the millions of individuals who navigate similar journeys, seeking relief from pain and improved quality of life.

n

FORWARD, the organization at the heart of this discussion, stands as a beacon for these patients. As a non-profit entity, it has carved out a crucial niche in the medical landscape by creating a robust platform for individuals with arthritis and other rheumatic diseases to actively participate in research. This participation manifests in various ways, primarily through the sharing of their personal health data and life experiences. The organization’s mission is clear: to provide a "full picture" of what it means to live with a rheumatic condition, extending beyond the immediate, often limited, scope of a clinical consultation.

n

The roster of conditions addressed by FORWARD is extensive, encompassing prevalent diseases such as Rheumatoid Arthritis (RA), Lupus, Psoriasis, Psoriatic Arthritis, Fibromyalgia, Axial Spondyloarthritis, Dupuytren Disease, Osteoarthritis, and even common ailments like low back pain, alongside many other rheumatic conditions. This broad spectrum ensures that a vast population of affected individuals can contribute to and benefit from FORWARD’s initiatives.

n

Ultimately, FORWARD aims to advance knowledge with the ambitious goal of helping millions of people live free of pain and significantly improve their quality of life. This vision is supported by a dual approach: empowering patients with a voice in research and equipping healthcare professionals and researchers with invaluable real-world data and insights.

n

A Chronology of Patient Empowerment in Rheumatic Disease Research

n

The journey towards patient-centric research in rheumatology, while seemingly a modern concept, has roots in a growing recognition of the limitations of purely clinical data. Historically, medical research often operated within the confines of laboratory settings and controlled clinical trials, with patient input largely confined to symptom reporting during examinations. However, the complex, chronic, and highly individualized nature of rheumatic diseases began to expose the gaps in this traditional model.

n

The formal genesis of organizations like FORWARD can be traced to a pivotal shift in medical philosophy, gaining significant momentum in the late 20th and early 21st centuries. Researchers and clinicians increasingly understood that the impact of a chronic disease extends far beyond its measurable biological markers. Factors like daily pain, fatigue, mental health, social function, treatment adherence, and side effects profoundly influence a patient’s overall well-being and the real-world effectiveness of therapies.

n

Early 1980s-1990s: Emergence of Patient-Reported Outcomes (PROs)nThe concept of Patient-Reported Outcomes (PROs) began to gain traction. These were questionnaires and surveys designed to capture the patient’s perspective on their health status, symptoms, and quality of life. This marked an early, crucial step towards systematically integrating the patient’s voice into research. However, these efforts were often localized and lacked a centralized, longitudinal approach.

n

Late 1990s-Early 2000s: The Foundation of Dedicated Patient RegistriesnRecognizing the need for a more comprehensive and continuous data stream, organizations began to establish dedicated patient registries. FORWARD, initially known as the Nebraska Arthritis Registry, was founded in 1999 with precisely this vision. Its inception represented a proactive response to the growing demand for real-world evidence in rheumatology. The goal was to move beyond episodic clinical data and collect information over extended periods, providing insights into disease progression, long-term treatment effects, and the nuances of living with these conditions day-to-day.

n

2000s-Present: Expansion and Digital TransformationnOver the past two decades, FORWARD has steadily expanded its reach and sophistication. What began as a regional initiative evolved into a national databank, drawing participants from across the United States. This expansion was facilitated by advancements in technology, allowing for more efficient data collection, secure storage, and sophisticated analysis. The organization embraced digital platforms, making it easier for patients to contribute their experiences remotely and regularly.

n

The involvement of prominent figures like Dr. Drew Pinsky signifies a more recent, yet crucial, development: the increased public awareness and validation of patient advocacy in chronic disease management. Dr. Pinsky’s personal experience, spanning decades of living with RA, provides a powerful chronological narrative of how treatments and understanding have evolved, and critically, how much more there is to learn through patient collaboration. His journey underscores the lifelong nature of these conditions and the enduring need for sustained research efforts, driven by the very people affected.

n

Today, FORWARD continues to evolve, adapting to new research methodologies and technological capabilities, but its core mission remains steadfast: to empower patients as active participants in the scientific endeavor, translating their lived experiences into actionable data that drives medical progress.

n

Supporting Data: Quantifying the Impact of Rheumatic Diseases and FORWARD’s Contribution

n

Rheumatic diseases represent a vast and complex group of conditions that collectively affect millions worldwide, posing significant public health and economic challenges. The data paints a stark picture of their pervasive impact, further underscoring the vital role of organizations like FORWARD.

n

Prevalence and Burden:

n

n
• Rheumatoid Arthritis (RA): Affects approximately 1.3 million adults in the U.S. and is a leading cause of disability. It can shorten life expectancy by several years if not adequately managed.

n

• Osteoarthritis (OA): The most common form of arthritis, affecting over 32.5 million adults in the U.S. It is a major cause of chronic pain and functional limitation.

n

• Lupus: An autoimmune disease affecting at least 1.5 million Americans, predominantly women, often leading to organ damage and severe systemic inflammation.

n

• Fibromyalgia: Characterized by widespread chronic pain, fatigue, and sleep disturbances, affecting an estimated 2-4% of the population, often leading to significant impairment in quality of life.

n

• Psoriatic Arthritis: Affects up to 30% of people with psoriasis, causing joint inflammation and skin lesions.

n

The economic burden associated with rheumatic diseases is staggering, encompassing direct medical costs (doctor visits, medications, surgeries) and indirect costs (lost productivity due to disability, premature mortality). Estimates suggest that arthritis and other rheumatic conditions cost the U.S. economy hundreds of billions of dollars annually. Beyond financial costs, the human toll in terms of chronic pain, reduced mobility, psychological distress, and diminished quality of life is immeasurable.

FORWARD’s Unique Data Contribution:
FORWARD’s strength lies in its ability to collect Patient-Reported Outcomes (PROs) on a massive scale and over extended periods. This longitudinal data provides insights that traditional clinical trials, often short-term and with highly selected patient populations, cannot capture.

• Longitudinal Tracking: Unlike a single clinic visit, FORWARD’s participants regularly report on their symptoms, treatment regimens, side effects, functional status, and overall well-being. This allows researchers to observe disease trajectories, the long-term effectiveness of therapies, and how patients adapt over years, not just months.
• Real-World Effectiveness: Clinical trials demonstrate a drug’s efficacy under ideal conditions. FORWARD’s data reveals its effectiveness in the real world, where patients have comorbidities, varying adherence patterns, and diverse lifestyles. This helps identify which treatments work best for which patient subgroups outside of controlled environments.
• Comprehensive Symptom Tracking: Beyond joint swelling or inflammatory markers, FORWARD collects data on pain levels, fatigue, sleep quality, mental health (depression, anxiety), and the impact of disease on daily activities, work, and social life. This holistic view is crucial for understanding the true burden of disease.
• Side Effect Profiles: Patients often experience a range of side effects that may not be fully captured in clinical trials. FORWARD’s data provides valuable insights into the frequency and severity of side effects in a broader patient population, informing both prescribers and patients.
• Healthcare Utilization: The databank can track how often patients visit doctors, are hospitalized, or use other healthcare services, providing data on the overall burden on the healthcare system and the economic impact of different treatment strategies.
• Underrepresented Populations: FORWARD strives to include a diverse range of participants, which helps to ensure that research findings are applicable to a broader population, including those often underrepresented in traditional trials.

This rich, patient-driven dataset empowers FORWARD to:

• Identify unmet needs: Pinpoint areas where current treatments fall short or where new therapeutic approaches are urgently required.
• Inform clinical guidelines: Provide evidence that helps shape best practices for managing rheumatic diseases.
• Accelerate drug development: Offer insights to pharmaceutical companies on what matters most to patients and the real-world performance of their products.
• Educate healthcare professionals: Equip clinicians with a deeper understanding of their patients’ experiences beyond the exam room.

By transforming individual stories into collective data, FORWARD provides the empirical foundation necessary to drive meaningful change in the lives of millions.

Official Responses: Voices from FORWARD and the Medical Community

The leadership and medical experts associated with FORWARD articulated the profound impact of the organization’s work, emphasizing the collaborative spirit and the scientific rigor that underpin its mission.

Dr. Kaleb Michaud, PhD, Director of FORWARD:
"Our conversation with Dr. Drew Pinsky truly underscores the essence of what FORWARD strives to achieve," stated Dr. Michaud. "Dr. Pinsky’s personal battle with Rheumatoid Arthritis highlights the universal need for patients to have a significant voice in the research that directly impacts their lives. As a director, my focus is on ensuring that the data we collect is not only vast but also scientifically robust and actionable. We are meticulously tracking the experiences of thousands of individuals, transforming their daily struggles and triumphs into quantifiable evidence that can inform new treatments, refine existing ones, and ultimately, improve patient outcomes. It’s about moving beyond assumptions and truly understanding the disease from the patient’s perspective."

Rebecca Schumacher, Executive Director of FORWARD:
"Our mission at FORWARD is clear: to advance knowledge about rheumatic conditions to help millions live free of pain and improve their quality of life," explained Rebecca Schumacher. "As Executive Director, I see firsthand the dedication of our team and the incredible generosity of our participants. We are not just collecting data; we are building a community where patients feel heard and valued. We are providing a crucial link between the lived experience of arthritis and the scientific advancements needed to combat these diseases. Our success hinges on continued patient participation and philanthropic support, which allows us to sustain our research infrastructure and expand our reach."

Dr. Ted Mikuls, Physician and Researcher:
Dr. Mikuls, a prominent figure in rheumatology research, emphasized the critical value of FORWARD’s databank for the broader scientific community. "From a researcher’s standpoint, the longitudinal, patient-reported data collected by FORWARD is invaluable," Dr. Mikuls commented. "Traditional clinical trials, while essential, have limitations. They often don’t capture the full spectrum of disease progression, the long-term impact of treatments, or the diverse experiences of patients in their daily lives. FORWARD provides that missing piece. It allows us to identify trends, understand real-world effectiveness, and generate hypotheses that can lead to breakthrough discoveries. This kind of real-world evidence is increasingly vital for developing more effective and patient-centered therapies."

Teresa Kerkman, FORWARD Team Member:
Teresa Kerkman, deeply involved in the operational aspects of FORWARD, echoed the sentiment of patient empowerment. "My role involves facilitating the direct connection between patients and research," Kerkman explained. "We work tirelessly to ensure that joining FORWARD is an accessible and meaningful experience for everyone. Whether someone has RA, lupus, fibromyalgia, or osteoarthritis, their story is unique and incredibly important. We help ensure that these individual narratives are woven into a larger fabric of data that informs the medical community. It’s truly inspiring to see how a patient’s willingness to share their journey can contribute to a future where others might experience less pain and a better quality of life."

The collective sentiment from FORWARD’s leadership and scientific advisors underscores a unified vision: to harness the power of patient experience through rigorous data collection and analysis, thereby accelerating the pace of discovery and improving the lives of individuals affected by rheumatic diseases.

Implications: Shaping the Future of Rheumatic Disease Management

The work undertaken by FORWARD, highlighted by the recent discussion with Dr. Drew Pinsky, carries profound implications for the future landscape of rheumatic disease management, impacting research, clinical practice, and patient advocacy alike.

1. Accelerated and More Relevant Research:
By providing a massive, longitudinal dataset of patient-reported outcomes, FORWARD directly accelerates research. Scientists gain access to real-world evidence that can:

• Inform drug development: Pharmaceutical companies can use this data to understand patient needs better, design more relevant clinical trials, and evaluate the real-world performance of new therapies.
• Identify therapeutic gaps: The data can pinpoint areas where existing treatments are insufficient, driving research into novel mechanisms of action or combination therapies.
• Personalized medicine: Insights from diverse patient populations can help identify biomarkers or patient characteristics that predict response to certain treatments, moving closer to truly personalized medicine in rheumatology.

2. Enhanced Clinical Practice and Healthcare Professional Knowledge:
FORWARD’s data enriches the understanding of healthcare professionals, enabling them to:

• Offer more holistic care: Clinicians gain a deeper appreciation for the day-to-day challenges their patients face, beyond what’s visible in a clinic setting. This encourages a more comprehensive approach to care that addresses pain, fatigue, mental health, and functional limitations.
• Improve patient-provider communication: With a better understanding of the patient perspective, providers can engage in more empathetic and effective communication, leading to shared decision-making.
• Tailor treatment strategies: Armed with real-world data on treatment effectiveness and side effects across diverse patient groups, clinicians can make more informed decisions about which therapies are most likely to benefit individual patients.

3. Empowered Patients and Stronger Advocacy:
The very act of participation in FORWARD empowers patients:

• Validation of experience: Knowing their personal story contributes to a larger scientific effort validates their struggles and provides a sense of purpose.
• Informed self-advocacy: Patients become more informed about their condition and the research landscape, enabling them to advocate more effectively for their own care.
• Collective strength: FORWARD fosters a sense of community, allowing patients to realize they are not alone in their journey and that their collective voice can drive significant change. This strengthens patient advocacy efforts at local, national, and even international levels, pushing for better policies, funding, and access to care.

4. A Paradigm Shift Towards Participatory Medicine:
FORWARD’s model is a leading example of participatory medicine, where patients are not just recipients of care but active contributors to medical knowledge. This shift has broader implications for how medical research is conducted across all chronic diseases, moving towards a more collaborative, patient-centered paradigm.

5. Realizing the Vision of a Pain-Free Life:
Ultimately, the most significant implication is the potential to achieve FORWARD’s ambitious vision: helping millions live free of pain and improve their quality of life. By systematically gathering and analyzing patient experiences, FORWARD provides the insights necessary to:

• Develop more effective pain management strategies.
• Discover disease-modifying therapies that prevent or reverse disease progression.
• Improve functional outcomes, allowing individuals to maintain independence and engagement in daily life.
• Reduce the overall burden of rheumatic diseases on individuals, families, and healthcare systems.

The call to action for patients to join FORWARD and share their stories is not merely an invitation to participate in a study; it is an invitation to be part of a movement. Similarly, the plea for donations is an investment in a future where chronic pain and disability from rheumatic diseases become less common, and a life of improved quality and freedom from suffering becomes a reality for more people. The collaboration between prominent figures like Dr. Drew Pinsky and dedicated organizations like FORWARD signifies a powerful, collective stride towards a healthier future for all those touched by rheumatic conditions.